NCT00997334View on ClinicalTrials.gov

Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

May 31, 2015

Study Completion Date

January 31, 2017

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Erlotinib

Trial Locations (2)

02115

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Genentech, Inc.

INDUSTRY

lead

David M. Jackman, MD

OTHER